Experimental motor neurone disease therapy shows early promise – PharmaTimes

An experimental therapy developed to address the genetic cause of a Amyotrophic lateral sclerosis (ALS), rare form of motor neurone disease (MND) has shown encouraging results in early research supported by the NIHR.

The phase 1-2 study, supported by the National Institute for Health Research and published in the New England Journal of Medicine, has shown tofersen is safe and well tolerated in people with a genetic form of MND.

Click here to read full article http://www.pharmatimes.com/news/experimental_motor_neurone_disease_therapy_shows_early_promise_1344775

Font Resize